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Background
Recent work has highlighted glutaminase (GLS) as a key
player in cancer cell metabolism, providing glutamine-
derived carbon and nitrogen to pathways that support
proliferation. There is significant interest in targeting
GLS for cancer therapy however the gene is not
frequently mutated or amplified in tumors. As a result,
identification of tractable markers that predict GLS
dependence is needed for translation of GLS inhibitors
to the clinic.
Materials and methods
Cells were engineered to overexpress an enzymatically
active variant of GLS1 that does not bind the previously
described GLS1 inhibitor, BPTES (bis-2-(5-phenylaceta-
mido-1,2,4-thiadiazol-2-yl)ethyl sulfide), to validate the
on-target effects of the drug and utility as a specific tool
compound. A panel of NSCLC cells were screened with
BPTES and the effects on proliferation were correlated
with transcriptional/genetic markers.
Results
Low E-cadherin and high vimentin expression, hallmarks
of a mesenchymal phenotype, marked NSCLC cells that
are particularly sensitive to inhibition of GLS1. Further-
more, lung cancer cells induced to undergo epithelial to
mesenchymal transition (EMT) acquired sensitivity to the
GLS inhibitor. Metabolic studies suggested that the
mesenchymal cells have a reduced capacity for oxidative
phosphorylation and increased susceptibility to oxidative
stress, rendering them unable to cope with the perturba-
tions induced by GLS inhibition.
Conclusions
These findings elucidate selective metabolic dependencies
of mesenchymal lung cancer cells and suggest novel
pathways to target in this aggressive cancer type.
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